Annual SGA
$25.55 M
-$10.93 M-29.96%
December 31, 2023
Summary
- As of February 8, 2025, SPRO annual SGA is $25.55 million, with the most recent change of -$10.93 million (-29.96%) on December 31, 2023.
- During the last 3 years, SPRO annual SGA has risen by +$4.11 million (+19.19%).
- SPRO annual SGA is now -38.72% below its all-time high of $41.70 million, reached on December 31, 2021.
Performance
SPRO SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$5.20 M
-$335.00 K-6.05%
September 30, 2024
Summary
- As of February 8, 2025, SPRO quarterly SGA is $5.20 million, with the most recent change of -$335.00 thousand (-6.05%) on September 30, 2024.
- Over the past year, SPRO quarterly SGA has dropped by -$1.24 million (-19.20%).
- SPRO quarterly SGA is now -66.04% below its all-time high of $15.30 million, reached on March 31, 2022.
Performance
SPRO Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$1.66 B
+$3.51 M+0.21%
September 30, 2024
Summary
- As of February 8, 2025, SPRO TTM SGA is -$1.66 billion, with the most recent change of +$3.51 million (+0.21%) on September 30, 2024.
- Over the past year, SPRO TTM SGA has dropped by -$1.68 billion (-6577.13%).
- SPRO TTM SGA is now -3542.53% below its all-time high of -$45.44 million.
Performance
SPRO TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
SPRO Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -30.0% | -19.2% | -6577.1% |
| 3 y3 years | +19.2% | -19.2% | -6577.1% |
| 5 y5 years | +98.3% | -19.2% | -6577.1% |
SPRO Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -38.7% | at low | -66.0% | at low | -25.5% | +3.9% |
| 5 y | 5-year | -38.7% | +63.9% | -66.0% | +37.3% | -145.5% | +3.9% |
| alltime | all time | -38.7% | +1060.5% | -66.0% | +198.7% | -3542.5% | +3.9% |
Spero Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $5.20 M(-6.1%) | $23.08 M(-2.2%) |
| Jun 2024 | - | $5.53 M(-6.5%) | $23.59 M(-2.3%) |
| Mar 2024 | - | $5.92 M(-8.0%) | $24.15 M(-5.5%) |
| Dec 2023 | $25.55 M(-30.0%) | $6.43 M(+12.7%) | $25.55 M(-0.2%) |
| Sep 2023 | - | $5.71 M(-6.4%) | $25.62 M(-3.5%) |
| Jun 2023 | - | $6.10 M(-16.7%) | $26.54 M(-6.9%) |
| Mar 2023 | - | $7.32 M(+12.7%) | $28.50 M(-21.9%) |
| Dec 2022 | $36.48 M(-12.5%) | $6.50 M(-2.1%) | $36.48 M(-15.2%) |
| Sep 2022 | - | $6.63 M(-17.6%) | $43.01 M(-9.5%) |
| Jun 2022 | - | $8.05 M(-47.4%) | $47.53 M(-2.4%) |
| Mar 2022 | - | $15.30 M(+17.5%) | $48.71 M(+16.8%) |
| Dec 2021 | $41.70 M(+94.5%) | $13.02 M(+16.8%) | $41.70 M(+15.3%) |
| Sep 2021 | - | $11.15 M(+20.8%) | $36.18 M(+19.3%) |
| Jun 2021 | - | $9.23 M(+11.2%) | $30.34 M(+18.3%) |
| Mar 2021 | - | $8.30 M(+10.7%) | $25.65 M(+19.7%) |
| Dec 2020 | $21.44 M | $7.50 M(+41.2%) | $21.44 M(+20.9%) |
| Sep 2020 | - | $5.31 M(+16.8%) | $17.73 M(+7.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2020 | - | $4.55 M(+11.3%) | $16.55 M(+4.8%) |
| Mar 2020 | - | $4.09 M(+8.0%) | $15.79 M(+1.3%) |
| Dec 2019 | $15.59 M(+21.0%) | $3.79 M(-8.4%) | $15.59 M(+0.9%) |
| Sep 2019 | - | $4.13 M(+9.3%) | $15.45 M(+6.9%) |
| Jun 2019 | - | $3.78 M(-2.7%) | $14.45 M(+5.3%) |
| Mar 2019 | - | $3.89 M(+6.5%) | $13.73 M(+6.5%) |
| Dec 2018 | $12.89 M(+18.9%) | $3.65 M(+16.4%) | $12.89 M(+9.9%) |
| Sep 2018 | - | $3.13 M(+2.4%) | $11.73 M(-4.2%) |
| Jun 2018 | - | $3.06 M(+0.5%) | $12.25 M(+0.8%) |
| Mar 2018 | - | $3.04 M(+22.2%) | $12.14 M(+12.0%) |
| Dec 2017 | $10.84 M(+50.1%) | $2.49 M(-31.8%) | $10.84 M(+2.6%) |
| Sep 2017 | - | $3.65 M(+23.5%) | $10.57 M(+19.8%) |
| Jun 2017 | - | $2.96 M(+69.9%) | $8.82 M(+50.4%) |
| Mar 2017 | - | $1.74 M(-21.6%) | $5.87 M(+42.2%) |
| Dec 2016 | $7.22 M(+228.0%) | $2.22 M(+16.2%) | $4.13 M(+116.2%) |
| Sep 2016 | - | $1.91 M | $1.91 M |
| Dec 2015 | $2.20 M | - | - |
FAQ
- What is Spero Therapeutics annual SGA?
- What is the all time high annual SGA for Spero Therapeutics?
- What is Spero Therapeutics annual SGA year-on-year change?
- What is Spero Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Spero Therapeutics?
- What is Spero Therapeutics quarterly SGA year-on-year change?
- What is Spero Therapeutics TTM SGA?
- What is the all time high TTM SGA for Spero Therapeutics?
- What is Spero Therapeutics TTM SGA year-on-year change?
What is Spero Therapeutics annual SGA?
The current annual SGA of SPRO is $25.55 M
What is the all time high annual SGA for Spero Therapeutics?
Spero Therapeutics all-time high annual SGA is $41.70 M
What is Spero Therapeutics annual SGA year-on-year change?
Over the past year, SPRO annual SGA has changed by -$10.93 M (-29.96%)
What is Spero Therapeutics quarterly SGA?
The current quarterly SGA of SPRO is $5.20 M
What is the all time high quarterly SGA for Spero Therapeutics?
Spero Therapeutics all-time high quarterly SGA is $15.30 M
What is Spero Therapeutics quarterly SGA year-on-year change?
Over the past year, SPRO quarterly SGA has changed by -$1.24 M (-19.20%)
What is Spero Therapeutics TTM SGA?
The current TTM SGA of SPRO is -$1.66 B
What is the all time high TTM SGA for Spero Therapeutics?
Spero Therapeutics all-time high TTM SGA is -$45.44 M
What is Spero Therapeutics TTM SGA year-on-year change?
Over the past year, SPRO TTM SGA has changed by -$1.68 B (-6577.13%)